U.S. MEIBOMIAN GLAND DYSFUNCTION MARKET ANALYSIS

The U.S. Meibomian Gland Dysfunction market is estimated to be valued at US$ 3,037.5 million in 2023 and is expected to exhibit a CAGR of 15.6% during the forecast period (2023-2030).

Analysts’ Views on U.S. Meibomian Gland Dysfunction Market:

The increasing research and development (R&D) activities for meibomian gland dysfunction, and  increasing prevalence of meibomian gland dysfunction which is expected to propel the market growth over forecast period .

Figure 1. U.S. Meibomian Gland Dysfunction Market Share (%), By Drug Type, 2023

To learn more about this report, request sample copy

U.S. Meibomian Gland Dysfunction Market – Driver

• Increasing prevalence of meibomian gland dysfunction syndrome: Increasing prevalence of meibomian gland dysfunction syndrome is expected to propel the growth of the U.S. meibomian gland dysfunctions market over the forecast period. For instance, according to a study published by the American Optometric Association in 2021, more than 16 million Americans, including twice as many women than men, were suffering from dry eye disease, and out of them around 70% of patients had meibomian gland disease. Moreover, according to the Fellow of the American College of Surgeons in January 2020, meibomian gland disease (also referred to as evaporative dry eye), is one of the most common causes of dry eyes across the globe. An estimated 50 to 70% of the elderly population has some degree of dry eye and nearly 70% of dry eye involves at least some degree of meibomian gland disease.
• Increasing excess usage of computers and mobile screens: The increasing excess usage of computers and mobile screens is expected to increase the incidence of meibomian gland dysfunction over the period of time and is also expected to aid in the growth of the market. People who frequently use computers or video screens are at high risk of developing meibomian gland dysfunction, as using screens for a long duration can lead to reduced blinking and tear production. Digital device usage has increased significantly in recent years among all age groups, due to extensive use for social and professional purposes. For instance, an article published in the National Library of Medicine Journal in March 2020, reported blue light emitted by digital screens can lead to symptoms of dry eyes which cause meibomian gland dysfunction. Exposure to blue light (range of 400–500 nm) can be harmful to the retina. Longer duration and less intense light exposure can also induce photochemical damage in the eyes.

Figure 2. . U.S. Meibomian Gland Dysfunction Market Share (%), By Distribution Channel, 2023

To learn more about this report, request sample copy

U.S. Meibomian Gland Dysfunction Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the U.S. Meibomian Gland Dysfunction market. During the lockdown, people's screen time (irrespective of their age) increased significantly, which had a severe impact, and an increase in ophthalmic disorders was observed. For instance, a research study published in December 2021 stated that both dry eye disease (DED) patients and healthy participants up to the age of 60 experienced worsening dry-eye symptoms during the COVID-19 lockout due to increased visual display terminal (VDT) period. The study also reported that younger persons had more severe dry-eye problems than older respondents, particularly during the lockdown. Therefore, the market gained traction as the restrictions were lifted. Since the pandemic led to an increase in dry eye disease cases globally. Hence, it is expected to propel the market growth during the forecast period.

U.S. Meibomian Gland Dysfunction Market Segmentation:

The U.S. meibomian gland dysfunction market report is segmented into Drug Type, By Route of Administration, and By Distribution Channel

• By Drug Type, the market is segmented into Cyclosporine, Omega-3 supplements, Antibacterial Eye Drops, Steroids, AZR MD 001, TP 03, NOV03 (Novatears), and HY02–Minocycline Out of which, the Cyclosporine segment is expected to hold a dominant position in the U.S. meibomian gland dysfunction market during the forecast period and this is attributed to the increasing awareness of meibomian gland dysfunctions.
• By Route of Administration, the market is segmented into Oral and Topical. Out of which, the Oral segment is expected to hold a dominant position in the U.S. meibomian gland dysfunction market during the forecast period and this is attributed to increasing prevalence of meibomian gland dysfunctions.
• By Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Out of which, the Hospital Pharmacies segment is expected to hold a dominant position in the U.S. meibomian gland dysfunction market during the forecast period and this is attributed to the increasing prevalence of meibomian gland dysfunctions.

U.S. Meibomian Gland Dysfunction Market: Key Developments

• In July 2020, The Ambu, a company that develops, produces, and markets diagnostic and life-supporting devices for hospitals and rescue services in North America, announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Scope ophthalmic.
• In October 2022, Aldeyra Therapeutics, Inc. discovers and develops innovative therapies designed to treat immune-mediated diseases,  completed the phase 3 clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for treating allergic conjunctivitis. The company presented the clinical data from the trial at the American Academy of Optometry 2022 Annual Meeting.
• In April 2021, Hill-Rom Holdings Inc (Hillrom), a medical technology company that offers patient support systems, surgical solutions, and front-line care products, company introduced the Welch Allyn PanOptic Plus Ophthalmoscope devices that boast a 20X larger viewing area. Welch Allyn PanOptic Plus Ophthalmoscope and Welch Allyn MacroView Plus Otoscope Give Caregivers Better, Bolder, Brighter Views to Help Support Earlier Diagnosis and Treatment
• In January 2022, Wassenburg Medical B.V., a company that provides endoscope reprocessing products and solutions in the U.S., announced that it had acquired Custom Ultrasonics, a U.S.-based medical equipment manufacturer. This acquisition will create additional growth in the U.S. market for both companies.
• in January 2021, Kala Pharmaceuticals Inc. launched EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS is now available in national and regional United States pharmaceutical distribution centers. Patients with a prescription can access EYSUVIS through their local retail pharmacies or home delivery.
• in January 2022, Sun Pharma Canada Inc, a subsidiary of the India-based company Sun Pharmaceutical Industries Limited launched Cequa (cyclosporine ophthalmic solution 0.09 percent w/v), a calcineurin inhibitor immunomodulator. All these novel product launches may give the country a cutting edge in the market.

U.S. Meibomian Gland Dysfunction Market: Key Trends

People of various ages found living in this multi-screen world

People of various ages are found living in this multi-screen world. Computer or digital screen use may cause less blinking, which may contribute to symptoms of dry eye disease (DED), thereby, increasing the demand for better and more effective therapeutics against DED which is expected to fuel growth in the studied market in the North America region. For instance, an article published in Cureus Journal in July 2022 stated that the prevalence of DED has been estimated at 21% in Canada. Women who used eye cosmetics were substantially more likely to have DED than the general population, which suggests that using eye cosmetics is one of the risk factors for developing DED. The high prevalence of the disease is estimated to boost market growth in the region during the forecast period.

U.S. Meibomian Gland Dysfunction Market: Restraint

Potential side effects of drugs

Potential side effects of drugs, such as steroids, used in the treatment of meibomian gland dysfunction syndrome have a wide range of side effects on the body of the patient who is continuously taking more than the prescribed dose of steroids for a longer period. This is expected to restrain the market growth during the forecast period. For Instance, according to an article published in the National Library of Medicine on April 05, 2023, Reported T-cell activation, immune checkpoint inhibitors are associated with multiple immune-related adverse events, one of which is immune checkpoint inhibitor-induced sicca syndrome. Exocrine gland damage leading to dry mouth and dry eyes were reported as adverse events following the use of nivolumab, durvalumab, and pembroliuzmab. Rheumatic complications were well reported in the literature, especially with regard to the sicca symptoms.

Market Players are taking initiatives for the safety and efficacy of drugs.

U.S. Meibomian Gland Dysfunction Market - Key Players

Major players operating in the U.S. Meibomian Gland Dysfunction market include Pfizer, Inc., AbbVie Inc., Johnson and Johnson Vision Care Inc., Bausch Health Companies Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., I-MED Pharma Inc., OASIS Medical, Sentiss Pharma Pvt. Ltd., RegeneRx, Akorn, Inc. AFT Pharmaceuticals, Alcon Inc., Horus Pharma,  Mitotech, Novaliq GmbH, Otsuka Pharmaceutical Co. Ltd, Prestige Consumer Healthcare, Santen Pharmaceutical Co. Ltd, Sun Pharmaceutical Industries Ltd, and VISUfarma.

*Definition: Meibomian gland dysfunction is a cause of dry eye syndrome (DES), also known as keratisis sicca and keratoconjunctivitis sicca. Patients with DES suffer damage to the ocular surface, instability in the tear film, and visual disturbance. Tear film covers the ocular surface, which is made up of three intertwined layers, a superficial lipid layer, produced by meibomian glands, which assists in reducing tear evaporation and uniform tear spreading, middle thick aqueous layer produced from lacrimal glands, and the innermost hydrophilic mucin layer produced from goblet cells of conjunctiva and epithelium of ocular surface.